Kolltan Pharmaceuticals' Series B - II Round

Kolltan Pharmaceuticals raised a round of funding on January 12, 2010.

Kolltan Pharmaceuticals is a clinical-stage company focused on the discovery and development of novel, antibody-based drugs targeting receptor tyrosine kinases (RTKs). Focused primarily in oncology an…

Articles about Kolltan Pharmaceuticals' Series B - II Round: